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Abstract 
Objective  To examine the association between hearing loss and cognitive function cross-sectionally and prospectively among older 
adults with atrial fibrillation (AF). Methods  Patients with AF ≥ 65-year-old (n = 1244) in the SAGE (Systematic Assessment of Geriatric 
Elements)-AF study were recruited from five internal medicine or cardiology clinics in Massachusetts and Georgia. Hearing was assessed by 
a structured questionnaire at baseline. Cognitive function was assessed by Montreal Cognitive Assessment (MoCA) at baseline and one year. 
Cognitive impairment was defined as score ≤ 23 on the MoCA. The associations between hearing loss and cognitive function were examined 
by multivariable adjusted logistic regression. Results  Participants with hearing loss (n = 451, 36%) were older, more likely to be male, and 
have depressive symptoms than patients without hearing loss. At baseline, 528 (42%) participants were cognitively impaired. Individuals 
with hearing loss were significantly more likely to have cognitive impairment at baseline [adjusted odds ratio (OR) = 1.37, 95% confidence 
interval (CI): 1.05–1.81]. Among the 662 participants who did not have cognitive impairment at baseline and attended the one-year follow-up 
visit, 106 (16%) developed incident cognitive impairment. Individuals with, versus those without, hearing loss were significantly more likely 
to develop incident cognitive impairment at one year (adjusted OR = 1.68, 95% CI: 1.07–2.64). Conclusions  Hearing loss is a prevalent 
but under-recognized factor associated with cognitive impairment in patients with AF. Assessment for hearing loss may be indicated among 
these patients to identify individuals at high-risk for adverse outcomes. 
J Geriatr Cardiol 2020; 17: 177183. doi:10.11909/j.issn.1671-5411.2020.04.002 
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1  Introduction 
Atrial fibrillation (AF) is the most common cardiac ar-
rhythmia with an increasing prevalence among older 
Americans.[1,2] Recently, AF has been associated with an 
increased risk of cognitive decline.[3,4] This is thought to be 
due to the occurrence of clinical strokes, subclinical embolic 
brain infarcts, and a high prevalence of other vascular risk 
factors associated with cognitive decline among patients 
with AF.[5,6] However, the association between AF and cog-
nitive decline is incompletely explained by these factors.[7] 
Moreover, most studies examining the association be-
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tween AF and cognitive decline have not considered the 
impact of non-cardiovascular conditions, which are risk 
factors for cognitive decline and are common in older men 
and women. Hearing loss is prevalent among the older as 
more than one-half of Americans > 70 years have hearing 
loss.[8] It is also independently associated with poor cogni-
tion[9] and accelerated cognitive decline[10] in the older. We 
previously reported a very high prevalence of hearing loss 
among older patients with AF,[11] and now speculate that 
older patients with AF with concomitant hearing loss are 
particularly vulnerable to cognitive decline. If this is true, 
screening for hearing loss among older patients with AF 
followed by hearing rehabilitative therapy may be worth 
testing in future studies to see whether it affects the trajec-
tory of their cognitive function. Currently, the United States 
Preventive Services Task Force does not endorse screening 
for hearing loss in the older given incomplete evidence.[12] 
The SAGE (Systematic Assessment of Geriatric Ele-
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ments)-AF study is an ongoing, prospective study enrolling 
patients with AF ≥ 65-year-old in whom serial comprehen-
sive examinations of geriatric conditions, including hearing 
and cognitive function, were performed. This provides a 
unique and timely opportunity to examine the association 
between hearing loss and cognitive function in older men 
and women with AF. 
2  Methods 
2.1  Study population 
The SAGE-AF cohort has been previously described.[13] 
In brief, the eligibility criteria include: (1) patients have an 
ambulatory visit at one of four Central Massachusetts prac-
tices (University of Massachusetts Memorial Health Care 
Internal Medicine, Cardiology, or Electrophysiology, Heart 
Rhythm Associates of Central Massachusetts), one practice 
in Eastern Massachusetts (Boston University Cardiology), 
or two practices in Central Georgia (Family Health Center 
and Georgia Arrhythmia Consultants); (2) AF is present on 
an electrocardiogram or Holter monitor or if it is noted in 
any clinic note or hospital record); (3) patients be aged 65 
years or older; and (4) patients have a CHA2DS2-VASc
[14] 
risk score ≥ 2. Participants are not eligible if they have an 
absolute contraindication to the receipt of oral anticoagula-
tion, if they have an indication for oral anticoagulation other 
than AF (i.e., mechanical heart valve), if they cannot pro-
vide informed consent, if they do not speak English, if they 
have a planned invasive high bleeding risk procedure, if 
they are prisoners, or if they are unwilling or unable to par-
ticipate in planned one- and two-year follow-up visits. 
A total of 1244 participants completed their baseline 
examination. A follow-up visit was performed one year 
after study baseline enrollment. All participants provided in-
formed written consent. Study protocols were approved by 
the University of Massachusetts Medical School, Boston Uni-
versity, and Mercer University Institutional Review Boards. 
2.2  Data collection 
Data on eligible and consenting patient’s demographic 
and clinical characteristics were abstracted from the medical 
record by trained study staff. Information abstracted in-
cluded participants’ age, sex, race, insurance type, comor-
bidities relevant to stroke and bleeding risk (e.g., diabetes, 
hypertension, heart failure, anemia, chronic kidney disease), 
and cardiovascular treatments (i.e., use of anti-platelets). 
2.3  Hearing assessment 
Hearing was assessed by three questions. (A) “Do you 
wear a hearing aid?” Response options are “Yes” or “No”; 
(B) “Do you have a hearing problem now? If you use a 
hearing aid, please answer the way you hear with a hearing 
aid.” Response options are “Yes” or “No”; and (C) “How 
much does your hearing interfere with your activities? If 
you use a hearing aid, please answer the way you hear 
WITH a hearing aid.” Response options include “Not a lot”, 
“A little”, “A moderate amount”, or “A lot”. A participant 
was characterized as having hearing loss if he/she answered  
“Yes” to questions (A) or (B), or “a moderate amount” or 
“A lot” to question (C). 
2.4  Cognitive function assessment 
Cognitive function was assessed by the Montreal Cogni-
tive Assessment Battery (MoCA),[15] a 30-item screening 
tool validated to detect mild cognitive impairment. The 
MoCA test examines global cognitive function with as-
sessments for memory, visuospatial ability, executive func-
tion, attention, concentration, working memory and orienta-
tion. Scores range from 0–30 with lower scores indicating 
poorer performance. The MoCA test was performed at 
baseline and one year later. Cognitive impairment was de-
fined as a score ≤ 23.[16] 
Because hearing loss may affect test performance on the 
MoCA, we also used the MoCA-auditory scoring which 
removes the three MoCA items heavily relying on hearing: 
language repetition (2 points), attention to letters (1 point), 
and digit span (2 points). After removal, the maximum 
MoCA score becomes 25, and the revised cutoff score for a 
“normal” score is 21/25 with 22/25 needed to pass).[17,18] 
Because there is no consensus as to what constitutes a clini-
cally meaningful difference in MoCA score, we chose not to 
examine MoCA as a continuous variable. 
2.5  Frailty and depression assessment 
Frailty is assessed using the Cardiovascular Health Sur-
vey frailty scale.[19] It has five components: weight loss/ 
shrinking, exhaustion, low physical activity, slow gait speed, 
and weakness. Each component receives a point and the 
scale ranges from 0–5. A participant is considered to be frail 
if three or more criteria are present, pre-frail (1–2), and not 
frail (0). The Patient Health Questionnaire (PHQ-9) was 
used to assess for depressive symptoms[20] with a score ≥ 5 
indicating high depressive symptoms. 
2.6  Statistical analysis 
Baseline characteristics of study participants were compared 
according to hearing status using analysis of variance for 
continuous variables and the χ2 test for categorical variables. 
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For the cross-sectional analysis, the association between 
hearing loss and cognitive impairment was examined by 
logistic regression. For the prospective analysis, among par-
ticipants without baseline cognitive impairment, the asso-
ciation between baseline hearing loss and incident cognitive 
impairment at one-year follow-up was also examined by 
logistic regression modelling. In regression Model 1, we 
controlled for age, sex, race, and education. In Model 2, we 
additionally adjusted for diabetes, hypertension, and stroke. 
Lastly, Model 3 further adjusted for the receipt of an oral 
anticoagulant agent. 
To evaluate the health-related effects of wearing a hear-
ing aid, we created a second definition of hearing loss. For 
this definition, individuals who only responded “Yes” to 
question (A) were not counted as having hearing loss. Only 
those who reported trouble hearing and/or those who say 
hearing problems interfere with daily activities are included. 
We adjusted for this variable in this manner, because simply 
adjusting for the use of a hearing aid may not have been 
adequate given the structure of our questionnaire. 
Statistical analyses were performed using SAS 9.4 (SAS 
Institute, Inc., Cary, North Carolina, USA). A two-sided 
P-value < 0.05 was considered to be statistically significant. 
3  Results 
The 1224 study participants were, on average, 75.8 ± 6.9 
years, 49% were women, and 84.9% were non-Hispanic 
white. A total of 1065 patients (86%) were prescribed an 
anticoagulant and 179 were not treated with anticoagulants 
based on either their personal preference or at the discretion 
of the treating physician. Hearing loss was prevalent and 
reported by 451 (36.3%) participants at baseline. Individuals 
with hearing loss were significantly older and less likely to 
be female. Stroke, depression, peripheral artery disease, and 
use of implantable cardiac device were more prevalent among 
individuals with, as compared to those without, hearing loss 
(Table 1). 
At baseline, 528 (42%) participants scored ≤ 23 on the 
MoCA, indicating the presence of at least mild cognitive 
impairment. Cross-sectionally, individuals with hearing loss 
were significantly more likely to be cognitively impaired 
[50% vs. 38%, odds ratio (OR) = 1.61, 95% confidence in-
terval (CI): 1.28–2.03]. This association remained signifi-
cant and only slightly attenuated after adjusting for demogra-
phic characteristics, education, vascular risk factors for cog-
nitive impairment, and anticoagulation therapy (adjusted 
OR = 1.37, 95% CI: 1.05–1.81) (Table 2). 
Among the 662 participants who did not have cognitive 
impairment at baseline and attended the one-year follow-up 
visit, 106 (16%) developed at least mild cognitive impair-
ment over this period. Individuals with hearing loss were 
significantly more likely to develop cognitive impairment at 
one year (21% vs. 14%, OR = 1.70, 95% CI: 1.11–2.60). 
This association remained essentially unchanged after ad-
justing for previously described potentially confounding 
factors of importance (Table 3). 
We built an additional model of age, gender, CHA2DS2- 
VASc, and depression. In this model, the OR (95% CI) for 
prevalent cognitive impairment of hearing loss was 1.17 
(0.91–1.51). The OR (95% CI) for incident cognitive im-
pairment of hearing loss was 1.48 (0.95–2.31). 
When hearing loss was defined by the criteria not in-
cluding the use of hearing aid, the results did not change 
substantially. The cross-sectional association between hear-
ing loss and baseline cognitive impairment was not statisti-
cally significant, though elevated (adjusted OR = 1.31, 95% 
CI: 0.98–1.74). Hearing loss remained significantly associ-
ated with the development of new onset cognitive impair-
ment during our one-year follow-up (adjusted OR = 1.63, 
95% CI: 1.02–2.60) (supplemental material, Table 1S & 
Table 2S). 
When the auditory MoCA was used, hearing loss was 
associated with prevalent cognitive decline (47% vs. 38%, 
OR = 1.40, 95% CI: 1.11–1.77). The association was not, 
however, statistically significant after multivariable adjust-
ment (adjusted OR = 1.13, 95% CI: 0.87–1.48). Prospec-
tively, incident cognitive impairment was more common in 
participants with hearing loss (22% vs. 16%, adjusted OR = 
1.53, 95% CI: 0.97–2.40) (supplemental material, Table 3S 
& Table 4S). 
4  Discussion 
Among older adults with AF seen in the ambulatory set-
ting, we demonstrated that self-reported hearing loss and 
cognitive impairment are both prevalent, affecting 36% and 
42% of individuals, respectively. Individuals with hearing 
loss were 60% more likely to have concomitant cognitive 
impairment and, more strikingly, were 70% more likely to 
develop cognitive impairment during the one-year follow-up. 
Multiple prospective and cross sectional studies have 
suggested that AF is a risk factor for cognitive impairment, 
cognitive decline, and dementia.[3,7,21] While the underlying 
mechanisms are likely multifactorial, clinical strokes and 
subclinical embolic brain infarcts are speculated as the main 
contributing factors.[5,6] In addition, cerebral hypoperfusion 
in the absence of clinical low output heart failure could play 
a role.[22] It has also been proposed that the association may  
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Table 1.  Characteristics of older adults with atrial fibrillation by self-reported hearing status. 
Hearing loss 
Characteristic 
Yes (n = 451) No (n = 793) 
P-value 
Age, yrs 77.9 ± 7.5 74.2 ± 6.5 < 0.01 
6574 169 (37.5%) 457 (57.6%) 
7584 183 (40.6%) 271 (34.2%) 
85 or older 99 (22.0%) 65 (8.2%) 
< 0.01 
Female 200 (44.4%) 407 (51.3%) 0.02 
Non-Hispanic white 398 (88.3%) 658 (83.0%) 0.01 
Education    
< = High school graduate 32 (7.3%) 68 (8.7%) 
Some college 218 (50.0%) 375 (48.0%) 
College graduate or above 189 (43.1%) 338 (43.2%) 
0.81 
Income, $    
Less than 10,000 18 (4.9%) 34 (5.1%) 
10,00049,999 181 (48.9%) 291 (43.5%) 
50,00099,999 102 (28.4%) 227 (33.9%) 
More than100,000 66 (17.9%) 117 (17.5%) 
0.21 
Insurance    
Commercial/HMO/PPO 74 (15.9%) 151 (18.9%) 
Medicare 334 (74.1%) 564 (71.1%) 
0.23 
Frailty    
Not frail 135 (29.9%) 278 (35.1%) 
Frail 63 (14.0%) 109 (13.8%) 
Pre-frail 253 (56.1%) 406 (51.2%) 
0.17 
CHA2DS2-VASc score 4.7 ± 1.6 4.3 ± 1.6 < 0.01 
Smoking    
Never 212 (47.0%) 382 (48.2%) 
Former 224 (49.7%) 391 (49.3%) 
Current 15 (3.3%) 20 (2.5%) 
0.69 
Alcohol abuse/dependency 133 (29.5%) 251 (31.7%) 0.43 
Medical history    
Heart failure 177 (39.3%) 286 (36.1%) 0.26 
Carotid disease 57 (12.6%) 76 (9.6%) 0.09 
Coronary artery disease 91 (20.2%) 151 (19.0%) 0.62 
Chronic renal disease 129 (28.6%) 227 (28.6%) 0.99 
Peripheral vascular disease 77 (17.1%) 102 (12.9%) 0.04 
Hypertension 410 (90.9%) 712 (89.8%) 0.52 
Diabetes 117 (25.9%) 229 (28.9%) 0.27 
Hyperlipidemia 364 (80.7%) 632 (79.7%) 0.67 
Stroke 57 (12.6%) 65 (8.2%) 0.01 
Implantable cardiac device 171 (37.9%) 250 (31.5%) 0.02 
Medication    
Aspirin 161 (35.7%) 281 (35.4%) 0.93 
Anticoagulant 386 (85.6%) 679 (85.6%) 
DOAC 157 (40.7%) 310 (45.6%) 
Warfarin 229 (59.3%) 369 (54.3%) 
0.11 
Depression 158 (35.0%) 195 (24.6%) < 0.01 
Anxiety 119 (26.4%) 174 (21.9%) 0.08 
Data are presented as means ± SD or n (%). DOAC: direct oral anticoagulant; HMO: health maintenance organization; PPO: preferred provider organization. 
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Table 2.  Association between hearing loss and prevalent cognitive impairment. 
OR (95% CI) 
Hearing loss 
Prevalent cognition  
impairment Unadjusted Model 1 Model 2 Model 3 
Yes (n = 451) 225 (50%) 1.61 (1.282.03) 1.38 (1.051.81) 1.38 (1.051.82) 1.37 (1.051.81) 
No (n = 793) 302 (38%) Reference 
Model 1: adjusted for age, sex, race, and education. Model 2: adjusted for variables in Model 1 plus diabetes, hypertension, and stroke. Model 3: adjusted for 
variables in Model 2 plus the receipt of anticoagulation. CI: confidence interval; OR: odds ratio. 
Table 3.  Association between hearing loss and incident cognitive impairment at one year. 
OR (95% CI) 
Hearing loss 
Incident cognitive  
impairment Unadjusted Model 1 Model 2 Model 3 
Yes (n = 208) 44 (21%) 1.70 ( 1.112.60) 1.65 (1.052.59) 1.68 (1.072.63) 1.68 (1.072.64) 
No (n = 454) 62 (14%) Reference 
Model 1: adjusted for age, sex, race, and education. Model 2: adjusted for variables in Model 1 plus diabetes, hypertension, and stroke. Model 3: adjusted for 
variables in Model 2 plus the receipt of anticoagulation. CI: confidence interval; OR: odds ratio. 
 
be due to shared risk factors for cognitive decline and AF, 
including factors such as older age, hypertension, diabetes, 
smoking, and heart failure. However, adjusting for these 
shared risk factors does not fully explain the observed asso-
ciation.[21] Meanwhile, very few if any studies[21] examining 
cognitive decline in AF have considered non-cardiovascular 
risk factors for cognitive impairment. In this context, this is 
the first study examining the effect of hearing loss, a condi-
tion very common in the geriatric population, in relation to 
cognitive function in patients with AF. 
Hearing loss has been associated with accelerated cogni-
tive decline and incident cognitive impairment among older 
adults.[10] In 1984 older adults from the Health ABC study, 
individuals with hearing loss on audiometric testing had a 
24% increase risk of incident cognitive impairment after 
six-year follow-up. Therefore, it is not surprising that the 
association was observed again in our AF population where 
the average age was 76 years old. What is striking is the 
high prevalence of hearing loss and cognitive impairment in 
this population. Because hearing loss was assessed by ques-
tionnaire instead of objective measurement, our study still 
likely underestimated the prevalence of hearing loss. It is 
possible that the questionnaire captures individuals with 
more severe hearing loss, because individuals with a milder 
form of this condition are more likely to underreport their 
hearing impairment.[23,24] Furthermore, rapid and significant 
cognitive decline in these individuals was observed after 
only one-year follow-up. Currently, hearing loss screening 
is not recommended in the older given the available lack of 
evidence.[12] Our study suggests that older adults with AF is 
a population in which hearing loss is very common and 
are vulnerable to cognitive decline. Therefore, hearing loss 
screening followed by application of hearing rehabilitative 
strategies may merit consideration in this population. Whe-
ther this approach reduces the rate of cognitive decline and 
improves quality of life in older individuals, irrespective of 
the presence of AF, deserves further research.[25] 
Patients with AF often have multiple comorbidities. In 
addition to the presence of several cardiovascular diseases, 
conditions common in the geriatric population such as de-
pression, anxiety, and frailty are also prevalent in older men 
and women with AF.[11,13,26,27] Traditionally, the three pillars 
of AF management are stroke prevention, rhythm control, 
and rate control. Recently, aggressive cardiovascular risk 
factor modification, including obesity and sleep apnea 
management, has emerged as the fourth pillar.[28] This find-
ing, along with other work from our group,[13,29] highlighted 
not only hearing loss and cognitive decline, but also other 
highly prevalent geriatric conditions in patients with AF, 
such as depression and frailty. These conditions certainly 
deserve physicians’ attention and we hope addressing them 
become the fifth pillar in the management of older individu-
als with AF. This approach is consistent with the recently 
proposed integrated or holistic approach in management of 
older patients with AF.[30] 
We also speculate that the triad of hearing loss, cognitive 
impairment, and AF may present physician-patient commu-
nication challenges with potential implications for patient 
understanding AF and its management, including increased 
difficulties with medication and monitoring. 
Furthermore, our finding suggests hearing loss can be a 
confounder in the association between AF and cognitive 
decline. Therefore, hearing loss and other conditions com-
mon in geriatric population deserve consideration in study-
ing the mechanism of AF on cognitive function. 
4.1  Strengths and limitations 
This is the first study which systemically assessed physi-
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cal, cognitive, and psychosocial conditions in patients with 
AF. Validated instruments were used to assess cognition, 
frailty, and mood. Also, the study population is geographi-
cally diverse and included patients with a high degree of 
comorbidities, emulating the real-world practice. Several 
limitations of this observational study need, however, to be 
kept in mind in its interpretation. Firstly, patient’s hearing 
status was assessed by questionnaire and was not objec-
tively measured. This approach likely underestimates the 
prevalence of hearing loss. On the other hand, objective 
hearing assessment requires expertise and can be time-con-
suming, which is not feasible in busy internal medicine or 
cardiology clinics. Secondly, the present follow up was for 
only one year, which likely underestimates the association 
between hearing loss and cognitive function among patients 
followed for longer periods of time. One possible risk factor 
for cognitive decline in elderly individuals is nocturnal 
blood pressure. We do not have that measured in the study. 
However, we used hypertension abstracted from the medical 
record and adjusted it in the models. Last but not least, we 
attempted to assess the effects of wearing a hearing aid by 
creating two definitions of hearing loss (including and ex-
cluding hearing aid). However, hearing treatment is com-
plex and patients using a hearing aid may be significantly 
different in many ways from those not using such a device, 
medically and socioeconomically.[10] Therefore, future studies 
are required to clarity the effect of use of hearing aids on 
cognitive function among older men and women with AF. 
4.2  Conclusions 
Hearing loss is a prevalent, easily assessed, and under-re-
cognized factor associated with cognitive impairment in 
patients with AF. Hearing loss is independently associated 
with prevalent cognitive impairment cross-sectionally and 
incident cognitive impairment after one-year follow-up. 
Screening for hearing loss may be indicated among older 
patients with AF to identify individuals at high-risk for ad-
verse outcomes. Assessment of hearing and other conditions 
common in geriatric population merits consideration in fu-
ture studies on the association between AF and cognitive 
impairment. 
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